{
    "organizations": [],
    "uuid": "61c824256b020f77f5b6f8de3421536c2bacc80c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-acceleron-plans-to-initiate-part-2/brief-acceleron-plans-to-initiate-part-2-of-ace-083-fshd-phase-2-trial-during-q2-of-2018-idUSASB0C04M",
    "ord_in_thread": 0,
    "title": "BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 18 PM / in 6 minutes BRIEF-Acceleron plans to initiate part 2 of ACE-083 FSHD phase 2 trial during Q2 of 2018 Reuters Staff 1 Min Read \nJan 8 (Reuters) - Acceleron Pharma Inc: \n* ACCELERON PHARMA INC - PLANS TO INITIATE PART 2 OF ACE-083 FSHD PHASE 2 TRIAL DURING Q2 OF 2018 \n* ACCELERON ANNOUNCES PRELIMINARY RESULTS FROM PART 1 OF THE ACE-083 PHASE 2 TRIAL IN PATIENTS WITH FACIOSCAPULOHUMERAL DYSTROPHY Source text for Eikon: Further company coverage:",
    "published": "2018-01-08T16:18:00.000+02:00",
    "crawled": "2018-01-08T16:33:58.019+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "plan",
        "initiate",
        "part",
        "fshd",
        "phase",
        "trial",
        "q2",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "acceleron",
        "pharma",
        "inc",
        "acceleron",
        "pharma",
        "inc",
        "plan",
        "initiate",
        "part",
        "fshd",
        "phase",
        "trial",
        "q2",
        "acceleron",
        "announces",
        "preliminary",
        "result",
        "part",
        "phase",
        "trial",
        "patient",
        "facioscapulohumeral",
        "dystrophy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}